G9651 – Psoriasis assessment tool documented not meeting any one of the specified benchmarks (e.g., (pga; 5-point or 6-point scale), body surface area (bsa), psoriasis area and severity index (pasi) and/or dermatology life quality index) (dlqi)) or psoriasis assessment tool not documented
HCPCS Level II code · G codes: Procedures / Professional Services (Temporary)
HCPCS codeG9651
- Long description
- Psoriasis assessment tool documented not meeting any one of the specified benchmarks (e.g., (pga; 5-point or 6-point scale), body surface area (bsa), psoriasis area and severity index (pasi) and/or dermatology life quality index) (dlqi)) or psoriasis assessment tool not documented
- Short description
- Psor as doc no spc bm
- Pricing indicator
00Not separately priced by Part B (bundled, not covered or Part A only)- Medicare coverage
CCarrier judgment – coverage decided by the Medicare contractor- BETOS category
Z2Undefined codes- Added
- January 1, 2016
- Last change
- January 1, 2019 – No change
Frequently asked questions
What is HCPCS code G9651?
G9651 is a HCPCS Level II code for psoriasis assessment tool documented not meeting any one of the specified benchmarks (e.g., (pga; 5-point or 6-point scale), body surface area (bsa), psoriasis area and severity index (pasi) and/or dermatology life quality index) (dlqi)) or psoriasis assessment tool not documented.
Does Medicare cover G9651?
The HCPCS file lists coverage code C: Carrier judgment – coverage decided by the Medicare contractor. Coverage and payment also depend on local coverage determinations and the patient’s plan.
Nearby G codes
- G9643 – Elective surgery
- G9644 – Patients who abstained from smoking prior to anesthesia on the day of surgery or procedure
- G9645 – Patients who did not abstain from smoking prior to anesthesia on the day of surgery or procedure
- G9646 – Patients with 90 day mrs score of 0 to 2
- G9647 – Patients in whom mrs score could not be obtained at 90 day follow-up
- G9648 – Patients with 90 day mrs score greater than 2
- G9649 – Psoriasis assessment tool documented meeting any one of the specified benchmarks (e.g., (pga; 5-point or 6-point scale), body surface area (bsa), psoriasis area and severity index (pasi) and/or dermatology life quality index) (dlqi))
- G9650 – Documentation that the patient declined therapy change or has documented contraindications (e.g., experienced adverse effects or lack of efficacy with all other therapy options) in order to achieve better disease control as measured by pga, bsa, pasi, or dlqi
- G9652 – Patient has been treated with a systemic or biologic medication for psoriasis for at least six months
- G9653 – Patient has not been treated with a systemic or biologic medication for psoriasis for at least six months
- G9654 – Monitored anesthesia care (mac)
- G9655 – A transfer of care protocol or handoff tool/checklist that includes the required key handoff elements is used
- G9656 – Patient transferred directly from anesthetizing location to pacu or other non-icu location
- G9657 – Transfer of care during an anesthetic or to the intensive care unit
- G9658 – A transfer of care protocol or handoff tool/checklist that includes the required key handoff elements is not used
- G9659 – Patients greater than or equal to 86 years of age who underwent a screening colonoscopy and did not have a history of colorectal cancer or other valid medical reason for the colonoscopy, including: iron deficiency anemia, lower gastrointestinal bleeding, familial adenomatous polyposis, lynch syndrome (i.e., hereditary non-polyposis colorectal cancer), inflammatory bowel disease (i.e., crohn's disease or ulcerative colitis), abnormal finding of gastrointestinal tract, weight loss, or changes in bowel habits
Source: CMS HCPCS Level II quarterly file, October 2026. Reference only – check payer policy before billing.